BBA分子基礎(chǔ)疾病涉及疾病過(guò)程和人類疾病模型的生物化學(xué)和分子遺傳學(xué)。該期刊涵蓋衰老，癌癥，代謝，神經(jīng)和免疫疾病等方面。特別鼓勵(lì)使用動(dòng)物模型來(lái)闡明每種條件下的生化和機(jī)械洞察力的手稿。手稿應(yīng)強(qiáng)調(diào)疾病途徑的潛在機(jī)制，并為理解和/或治療這些疾病提供新的貢獻(xiàn)。如果沒(méi)有全面審核，可能會(huì)拒絕高度描述性和方法開(kāi)發(fā)提交。鑒于巨大的miRNA網(wǎng)絡(luò)對(duì)基因表達(dá)的復(fù)雜調(diào)控，只有在描述單一miRNA對(duì)（疾病相關(guān)）基因的調(diào)控時(shí)才會(huì)考慮如果它們提供真正的，新穎的疾病機(jī)制洞察力的手稿。此外，除非他們提出真正新穎的見(jiàn)解，否則不會(huì)考慮限于單細(xì)胞系的研究。

BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. Given the complex regulation of gene expression by a vast network of miRNA's, manuscripts describing the regulation of (disease-associated) genes by single miRNAs will only be considered if they provide genuine, novel insight in a disease mechanism. Further, studies restricted to a single cell line will not be considered unless they present truly novel insights.